Alpa Laboratories Limited Stock Price Today (NSE: ALPA)

Alpa Laboratories Limited

61.12+0.73 (+1.21%)
Market Closed

Fundamental Score

...

Alpa Laboratories Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Alpa Laboratories Limited share price today is 61.12, up +1.21% on NSE/BSE as of 16 September 2026. Alpa Laboratories Limited (ALPA) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of 128.60 (Cr). The 52-week high for ALPA share price is 96.80 and the 52-week low is 46.10. At a P/E ratio of 36.38x, ALPA is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 8.39% and a debt-to-equity ratio of 0.01.

Alpa Laboratories Limited Share Price Chart — NSE/BSE Historical Performance

No data
High
69.50
Low
60.05
Volume
14.7K
Change
-9.09%

Alpa Laboratories Limited share price chart: -9.09% return over the past month. 52-week high ₹96.80, 52-week low ₹46.10.

Alpa Laboratories Limited — Last 10 Trading Days

DateOpenHighLowCloseVolume
60.0664.5059.4061.1214.77K (Cr)
62.0062.8060.0060.3910.74K (Cr)
62.9363.2061.0061.6910.63K (Cr)
63.2464.0262.1962.628.80K (Cr)
63.8064.4062.4963.2424.55K (Cr)
62.0065.0061.7063.1728.76K (Cr)
63.9963.9961.5062.173.39K (Cr)
64.0064.0061.5062.719.19K (Cr)
63.7964.6063.0563.305.83K (Cr)
61.7365.0061.3563.1318.73K (Cr)

Alpa Laboratories Limited — Last 12 Months Price History

MonthOpenHighLowCloseChange
63.9065.0059.4061.12-4.35%
67.5572.5060.0562.73-7.14%
69.2078.8965.0066.84-3.41%
72.5073.6966.6167.55-6.83%
66.1774.8066.0971.42+7.93%
50.6572.4748.6066.18+30.66%
66.8066.8046.1046.46-30.45%
68.0176.1864.4066.01-2.94%
77.8580.0861.0068.14-12.47%
78.6092.5075.0077.69-1.16%
90.2091.8675.5578.16-13.35%
90.0093.8585.9191.57+1.74%

Returns & Performance

Poor

Return on Equity (ROE)

8.39%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

9.28%

Returns generated on total capital deployed

Excellent

Oper. Profit Margin (5Y Avg)

13.30%

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Alpa Laboratories Limited Valuation Check

Poor

Price to Earnings (P/E)

36.38x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

34.89x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

57.29%

% shares held by company founders/management

Poor

FII Holding

0.38%

% shares held by foreign institutional investors

Poor

DII Holding

0.00%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Excellent

Profit Growth (Quarterly YoY)

165.09%

Net profit growth vs same quarter last year

Excellent

Revenue Growth (Quarterly YoY)

25.22%

Revenue growth vs same quarter last year

Poor

Revenue Growth (5-Year CAGR)

1.64%

Compounded annual revenue growth over 5 years

Excellent

EPS Growth (5-Year CAGR)

14.23%

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

23.66%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.01x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

65.72x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

14.47 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Alpa Laboratories Limited Fundamental Analysis & Valuation Benchmarking

Educational evaluation of ALPA across key market metrics for learning purposes.

Positive Indicators

8 factors identified

Robust Profit Growth (165.09%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture.

Strong Revenue Growth (25.22%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Strong Profit Growth Track Record (23.66% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model.

Conservative Debt Levels (D/E: 0.01)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (65.72x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Healthy Liquidity Position (Current Ratio: 4.10)

Observation: Strong short-term liquidity to meet obligations.

Analysis: Current ratio >1.5 indicates good working capital management.

Balanced Promoter Holding (57.29%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

5 factors identified

Below-Average Return on Equity (8.39%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Suboptimal ROCE (9.28%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.

Limited Growth History (1.64% CAGR)

Observation: Below-average 5-year sales growth trajectory.

Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.

Limited Institutional Interest (FII+DII: 0.38%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Alpa Laboratories Limited vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Alpa Laboratories Limited with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
60.3/100
61
₹128.60
36.4
Average
8.39%
Poor
9.28%
Poor
0.0
Excellent
23.66%
Excellent
1.64%
Average
0.00%
66.4/100
1840
₹441471.20
36.5
Average
14.74%
Average
19.31%
Good
0.0
Excellent
31.64%
Excellent
11.78%
Good
0.82%
56.3/100
9322
₹247033.00
84.6
Average
16.19%
Good
20.38%
Excellent
0.0
Excellent
5.29%
Good
8.67%
Good
0.41%
51.4/100
4966
₹168062.31
79.3
Average
27.07%
Excellent
14.09%
Average
1.8
Average
11.56%
Good
11.80%
Good
0.76%
74.1/100
1119
₹111686.18
24.9
Average
19.74%
Good
21.77%
Excellent
0.4
Excellent
18.76%
Excellent
12.45%
Good
0.09%
40.2/100
1366
₹110352.31
32.7
Average
11.82%
Average
15.67%
Good
0.0
Excellent
10.03%
Good
8.01%
Good
0.90%
34.1/100
1969
₹106375.23
97.2
Average
18.19%
Good
21.35%
Excellent
0.5
Excellent
-1.89%
Poor
7.19%
Good
0.13%
41/100
1166
₹97319.25
30.1
Average
11.75%
Average
14.80%
Average
0.2
Excellent
16.54%
Excellent
12.09%
Good
0.65%
24.6/100
1680
₹96655.69
26.2
Average
9.94%
Poor
14.54%
Average
0.2
Excellent
-8.07%
Poor
6.32%
Good
0.26%
83.4/100
2095
₹95793.88
17.3
Average
26.90%
Excellent
31.80%
Excellent
0.3
Excellent
34.39%
Excellent
13.02%
Good
0.72%
61.5/100
2280
₹94164.00
46.1
Average
12.49%
Average
13.56%
Average
0.4
Excellent
10.52%
Good
18.10%
Excellent
0.04%

Alpa Laboratories Limited PE Ratio History

Historical price-to-earnings ratio for ALPA — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 20248.01₹118.4614.8x
FY 20235.88₹103.3017.6x
FY 20226.70₹63.009.4x
FY 20213.45₹79.4023x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Alpa Laboratories Limited Quarterly Performance

Latest quarterly metrics for ALPA — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

25.22%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

165.09%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

1.64%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

23.66%

Compounded annual net profit growth over 5 years

Alpa Laboratories Limited Technical Indicators

SMA 50, SMA 200, RSI and volume signals for ALPA — calculated from daily price history

50RSI 14
Neutral — RSI 50

Momentum is balanced — neither overbought nor oversold.

SMA 50
66
▼ Price below SMA 50 — Short-term bearish
SMA 200
69
▼ Price below SMA 200 — Long-term downtrend
30-Day Avg Volume
16K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Alpa Laboratories Limited Financial Statements

Annual income statement, balance sheet and cash flow for Alpa Laboratories Limited (ALPA) — sourced from NSE/BSE filings.

Financial Results & Statements

Latest quarterly, annual and period-wise financial data for Alpa Laboratories Limited

Loading latest quarterly results...

About ALPA (Alpa Laboratories Limited)

Alpa Laboratories Ltd is a dynamic pharmaceutical company rooted in Indore, India, dedicated to the development, manufacturing, and distribution of a diverse range of pharmaceutica...l products. With a history stretching back to its incorporation, the company has steadily cultivated a reputation for quality and reliability within the Indian pharmaceutical landscape. Alpa Laboratories focuses on providing accessible and effective medications, aiming to cater to a broad spectrum of healthcare needs across various therapeutic areas. Their commitment to rigorous quality control and adherence to industry best practices ensures that their products meet the highest standards of safety and efficacy, solidifying their position as a trusted provider in the market. The company's enduring presence speaks to its commitment to innovation and service within the ever-evolving healthcare sector. Alpa Laboratories is characterized by its dedication to producing formulations that cover a wide range of therapeutic segments. This encompasses areas such as pain management, cardiovascular health, and anti-infectives, showcasing the company's breadth and ability to address numerous prevalent health concerns. The company demonstrates an understanding of the healthcare challenges facing India and strives to provide solutions through its comprehensive product portfolio. This diverse offering allows Alpa Laboratories to serve a broad patient base and contribute meaningfully to improved healthcare outcomes across the country. The firm's commitment to expanding its therapeutic reach underscores its ambition to be a significant contributor to the health and well-being of the Indian population. At its core, Alpa Laboratories operates with a vision of enhancing patient lives through access to quality pharmaceuticals. While firmly established in Indore, the company's influence extends across India, reaching patients and healthcare providers alike. Their established infrastructure and distribution network enable them to effectively deliver their products to various markets, ensuring accessibility and timely availability. Alpa Laboratories' steady growth trajectory reflects its focus on sustainable practices, continuous improvement, and a dedication to meeting the evolving needs of the healthcare industry. This unwavering commitment to excellence positions Alpa Laboratories for continued success and growth in the years to come.

Company Details

Symbol:ALPA
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Mahendra Singh Chawla
Chairman of the Board
Mr. Paresh Chawla
MD & Director
Mr. Bakulesh Chandulal Shah
Chief Financial Officer

ALPA Share Price: Frequently Asked Questions

What is the current share price of Alpa Laboratories Limited?

Alpa Laboratories Limited (ALPA) trades at ₹61.12 on NSE and BSE. Market cap ₹128.60 (Cr). Educational data only.

What is the P/E ratio of Alpa Laboratories Limited?

Alpa Laboratories Limited has a P/E of 36.38x vs industry average 34.89x.

What is the Bull Run score for Alpa Laboratories Limited?

Alpa Laboratories Limited has a Bull Run score of 60.3/100 based on 25+ financial parameters.

Does Alpa Laboratories Limited pay dividends?

Alpa Laboratories Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Alpa Laboratories Limited?

Alpa Laboratories Limited has ROE of 8.39%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Alpa Laboratories Limited?

Alpa Laboratories Limited has debt-to-equity of 0.01.

Is Alpa Laboratories Limited a good investment?

Bull Run gives Alpa Laboratories Limited a score of 60.3/100. This is not investment advice — consult a SEBI-registered advisor.